Medtronic To Acquire Twelve, Developer Of Transcatheter Mitral Valve Replacement Device DUBLIN – August 25, 2015 – In support of the company’s therapy innovation strategy, Medtronic plc (NYSE: MDT) today announced that it has signed a definitive agreement to acquire Twelve, Inc. (“Twelve”), a privately-held medical device company based in Redwood City, Calif., focused on […]

Two of the most anticipated new heart drugs to be launched in recent years have been priced well above analyst expectations, fuelling the debate about whether modern medicines cost too much. Praluent, made by Sanofi and Regeneron Pharmaceuticals, and Entresto from Novartis are both treatments that represent significant advances for millions of patients at risk […]

St. Jude Medical Inc (STJ.N) agreed to buy smaller rival Thoratec Corp (THOR.O) for about $3.4 billion, giving it more devices for patients with the highest risk of heart failure. St. Jude said on Wednesday it would offer $63.50 per Thoratec share, which represents a premium of about 10 percent to the stock’s Tuesday close. […]

The U.S. food and Drug Administration said it was strengthening an existing warning label that non-aspirin, non-steroidal anti-inflammatory drugs (NSAIDs) increase the chance of a heart attack or stroke. NSAIDs are used to treat pain and fever from medical conditions such as arthritis, menstrual cramps, headaches, colds, and the flu, and some of the better-known […]

The Food and Drug Administration strengthened its safety warnings about heart-attack and stroke risks linked to a class of common pain relievers that includes medicines such as Celebrex, Advil, Motrin IB and Aleve. The FDA said new data have caused it to conclude that the medicines—called NSAIDs, for nonsteroidal anti-inflammatory drugs—definitely cause an increased risk […]

It used to be that the major hurdle in getting a new drug approved was successfully completing phase 3 trials – the long-term studies needed to prove to regulators that your drug was both effective and safe. These trials can take years to run and cost hundreds of millions of dollars. Yet, despite doing successful […]

Novartis AG on Tuesday won U.S. approval for its keenly awaited new heart failure drug Entresto earlier than expected, boosting hopes for a medicine tipped by analysts to reap billions of dollars in annual sales. The Swiss drugmaker had previously said U.S. approval was likely in August. The U.S. Food and Drug Administration said in […]

Entresto, Novartis’s novel heart failure (HF) drug, gained FDA approval earlier today. The approval arrived six weeks ahead of the drug’s action date. Formerly known as LCZ 696, the drug had already received a fast track designation and an expedited review under the FDA’s priority review program. Novartis said the wholesale acquisition cost of Entresto will be $12.50 per […]

Older people who walk briskly, are moderately active in their free time, drink moderately, don’t smoke and avoid obesity may be half as likely to develop heart failure as people who don’t engage in these healthy habits, a new study suggests. Based on the findings, optimizing a few healthy lifestyle factors can cut heart failure […]

Novartis plans to test a novel pricing model with some customers when it launches its keenly awaited new heart failure drug Entresto, the Swiss company’s head of pharmaceuticals said on Tuesday. Entresto, also known as LCZ696, is the first new drug in decades for helping patients whose lives are in danger because their hearts cannot […]